Background: Cisplatin-based chemotherapy improves survival in advanced non-small-cell lung cancer. Using data from phase III trials of mitomycin, ifosfamide and cisplatin, this paper investigates whether the beneficial effect of chemotherapy on survival and quality of life seen overall is limited to certain patient subgroups.
Introduction
There is now a wide body of evidence demonstrating the beneficial effects of chemotherapy on survival in patients with advanced non-small-cell lung cancer. In particular, meta-analyses of 1780 patients with locally advanced disease from 11 randomised trials and 778 patients with extensive stage disease from eight trials both showed a significant survival advantage for patients receiving cisplatin-based chemotherapy [1] . The recently published results from two parallel phase III trials (MIC 1 and MIC 2) comparing mitomycin, ifosfamide and cisplatin chemotherapy (MIC) plus standard treatment with standard treatment alone, in patients with unresectable non-small-cell lung cancer, has provided further evidence in favour of chemotherapy [2] . Analysis of the combined data from these trials in 797 patients showed that MIC significantly improved survival (P = 0.02).
When considering the use of chemotherapy routinely for patients with unresectable non-small-cell lung cancer, considerable uncertainty remains as to whether the treatment is beneficial for all types of patient. In particular, the benefit of chemotherapy to patients of poor performance status is still in doubt, with some trials excluding patients with World Health Organisation performance status (PS) 2 or worse [3] . Performance status is well known to be one of the most powerful independent prognostic factors for survival in patients with advanced lung cancer, regardless of treatment [4] . Very little is known, however, about the impact of performance status on the chance of benefit from chemotherapy in this disease. Few studies have examined subgroups within advanced non-small-cell lung cancer in order to define those that may benefit more or less from chemotherapy. The analysis of subgroups is controversial [5] but as long as appropriate care is taken, useful information may be obtained [6, 7] . Subgroup analysis of a randomised trial comparing three different chemotherapy regimens, cisplatin plus vinorelbine vs. cisplatin plus vindesine vs. vinorelbine alone, showed that although cisplatin-based chemotherapy was found to be beneficial overall, this was not true in the PS 2 subgroup of patients [8] . The meta-analysis [1] examined the effect of cisplatin-based chemotherapy compared to no chemotherapy in subgroups specified by sex, age, stage, histology and performance status and found no difference in the size of treatment effect in any subgroup of patients. Meta-analysis combines results from different trials with varying treatments and performance scales and therefore the analysis of a large amount of data from a single source, as given here, is preferable. The aim of this paper is to investigate, using the combined data from the MIC trials, whether the beneficial effect of chemotherapy compared to non-chemotherapy standard treatment is limited to certain subgroups of patients. This is considered in terms of survival and quality of life endpoints.
Patients and methods

Trial design
Details of the design of the MIC 1 and MIC 2 trials are given elsewhere [2] , In summary, ambulatory (PS 0, 1 or 2) patients, aged 75 or less, with inoperable non-small-cell lung cancer were prospectively randomised to receive MIC chemotherapy plus standard treatment (MIC + ST) vs. standard treatment alone (ST). The trials were run concurrently by the same collaborative groups and had identical designs and eligibility criteria apart from stage of disease. The MIC 1 trial included patients with localised disease (inoperable 3A and nonbulky 3B) for which standard treatment was radical radiotherapy whilst patients in the MIC 2 trial had extensive stage disease (bulky 3B and 4) for which standard treatment was palliative care. A separate randomisation schedule was used for each trial and randomisation in MIC 1 was further stratified by radiotherapist to ensure that the variation in clinical practice was distributed evenly between the two arms. The primary endpoint for the studies was survival with toxicity, response to treatment and quality of life as secondary endpoints. The trials opened in March 1988 and closed for recruitment in March 1996
Survival analysis
The analysis relates to the combined data from the two trials with trial acting as a surrogate for stage of disease. Survival was measured from date of randomisation to either the date of death (all causes), censor date for the analysis (1 January 1997) or, if not observed up to that time, date last seen alive. The Kaplan-Meier method was used to estimate overall survival curves, with differences between treatments assessed using the log-rank test.
Comparison of the survival benefit of chemotherapy against standard treatment, assessed by the hazard ratio, was examined for the pre-planned subgroups specified by trial/stage (MIC 1/locally advanced and MIC 2/extensive stage) and also for sex, age (< 65 years and 65+ years), histology (squamous, adenocarcinoma. large cell undifferentiated) and performance status (0. I and 2). Hazard ratios for each subgroup were calculated using the log-rank expected and observed numbers of deaths (plotted as squares, with the size reflecting the number of patients in the subgroup and lines extending to 95% confidence limits). These were pooled across subgroups within each factor to give overall survival benefit stratified by that factor (plotted as diamonds, centred on the hazard ratio with extremities to 95% confidence limits). The overall unstratified hazard ratio is plotted as a dotted vertical line. Hazard ratios less than one indicate that survival with chemotherapy was superior to that for standard treatment.
Chi-square tests for heterogeneity (or interaction) [9] were used to assess the variability of the hazard ratios across subgroups within sex. age. histology and stage and a chi-square test for trend [9] was used to assess the trend in hazard ratios across levels of performance status. All P-values quoted are two-sided and statistical significance relates to results where the f-value is less than 5%.
Quality of life study
The quality of life study was carried out on a subset of trial patients. Details of the study are given in the main trial paper [2] . The questionnaire, designed specifically for the trial, was based on the lung cancer module of the quality of life questionnaire devised by the European Organisation for Research and Treatment of Cancer (EORTC QLQ-LC13). The trial questionnaire consisted of 12 questions assessing physical and psychological symptoms and toxicity, with responses recorded on a four-level ordered categorical scale (0 -none, 1 -a little, 2 -quite a bit, 3 -very much). The mean quality of life score, calculated from the responses to the 12 questions, is used as the outcome measure for analysis. This mean quality of life score ranges from 0 at best to 3 at worst. Assessments were made at approximately 0, 3,6, 9 and 12 weeks from randomisation. The analysis here, as in the main trial paper, focuses on the zero-to six-week change in mean quality of life score. Negative values in this measure imply that the level of symptom scores reduced over this time period, thus indicating an improvement in quality of life, and conversely, positive values imply deterioration. The treatment effect on this outcome is investigated for the three subgroups defined by levels of performance status. The analysis is purely descriptive because of the small numbers of patients in each of these subgroups. Subgroup analysis for the quality of life outcome was carried out only as a supplement to the findings from the survival outcome, and hence no subgroups other than those defined by performance status are analysed.
Results
In total, 797 eligible patients were included in the analysis, 446 from MIC 1 and 351 from MIC 2, giving in the combined data 398 patients on MIC + STand 399 on ST alone. At the time of analysis, 750 patients were dead and, with 8 lost-to-follow-up, the remaining 39 had an average follow-up of 30 months and a minimum of 12 months. The results from the MIC trials are detailed elsewhere [2] .
Survival analysis of the combined data ( Figure 1 ) showed that MIC significantly improved survival (P = 0.02), giving on average just over one and a half months extra survival time. The overall unstratified hazard ratio of 0.84 (95% confidence interval (95% CI): 0.73-0.97) shows a 16% reduction in the risk of death with chemotherapy. The hazard ratios for the two trials (Figure 2 ) show chemotherapy to reduce the risk of death for both stages of patient (0.86 for MIC 1 and 0.79 for MIC 2). The treatment effect was not significant for patients with localised disease (95% CI: 0.71-1.05) but was significant for those with extensive disease (95% CI: 0.63-0.97). The hazard ratios for the two trials did not differ significantly from each other (P = 0.53). The overall hazard ratio stratified by trial does not differ greatly from the unstratified result and remains statistically significant (0.83; 95% CT: 0.72-0.95).
The hazard ratios for all other subgroups, together with the stratified results are shown in Figure 3 . In subgroups defined by sex (599 males and 198 females), age (446 aged less than 65 years and 351 aged 65 or more) and histology (506 squamous, 152 adenocarcinomas (adeno) and 93 large cell undifferentiated (LCU)), chemotherapy appeared to be beneficial with all hazard ratios close to the overall treatment effect. In each case, there was no significant heterogeneity between the hazard ratios (P -0.22, P = 0.79, P = 0.82, respectively). In subgroups defined by performance status (252 with PS 0, 348 with PS I and 159 with PS 2), hazard ratios suggest a decreasing effectiveness with worsening performance status (0.75, 0.83 and 0.98 for PS 0, I and 2, respectively), with PS 2 patients appearing to gain no survival benefit from chemotherapy. This trend was not statistically significant (P = 0.22). PS 2 patients received a comparable number of courses of chemotherapy as other patients (52% of PS 2 patients had four courses compared to 57% overall) and thus the observed lack of effectiveness in this subgroup is not due to a reduced amount of treatment.
The quality of life study comprised 176 patients, with 48, 74 and 48 in the PS 0, I and 2 subgroups respectively (6 had unspecified performance status). One hundred thirty-four patients were included in the analysis (37, 61, 31 and 5 in PS 0, 1, 2 and unspecified, respectively). Two patients had an intermittent missing questionnaire and 40 patients dropped out of the quality of life study within the first six weeks of the study (due to death in 16 patients). Dropout rates were similar for the two treatment arms (22% vs. 24% overall and 6% vs. 10% deathrelated) but the dropout rate in the PS 2 patients was greater than the other levels of performance status (35% compared to 23% on PS 0 and 18% on PS 1). The overall zero-to six-week change in mean quality of life score is shown in Figure 4 , together with a breakdown by performance status. The overall results for 134 patients showed that on average, over the zero-to six-week time period, patients on chemotherapy improved (mean change = -0.14; 95% CI: -0.23 to -0.05) whilst patients on standard treatment deteriorated (mean change = 0.23; 95% CI: 0.09-0.38). When this is broken down by performance status, it is the PS2 patients that have the greatest improvement on chemotherapy (mean change = -0.27; 95% CI -0.45 to -0.09). The mean quality of life scores at baseline for patients of PS 0, 1 and 2 were 0.53, 0.80 and 0.99, respectively, so PS 2 patients have the worst quality of life at baseline and thus have the greater potential for palliation.
Discussion
The analysis of all patients in the MIC trial show that MIC chemotherapy is beneficial to survival. This confirms the findings from other studies of cisplatin-based therapy. The MIC trials were designed to investigate the treatment effects for locally advanced and extensive disease separately as well as overall. A separate randomisation schedule was used for each trial, ensuring comparable treatment groups within each stage and sample size was planned to ensure adequate power to detect treatment effects within each stage. Analysing the subgroups of patients within each trial showed a survival benefit of chemotherapy for both stages of patient but this was significant only in those with extensive disease.
The analysis of other subgroups defined by sex, age, histology and performance status was not planned and hence potentially unreliable [5] [6] [7] . For this reason, the subgroup analysis was treated purely as an exploratory, hypothesis-generating exercise, and not a hypothesistesting one [7] . The survival advantage was consistent in subgroups defined by sex, age and histology and also for patients of good performance status (i.e. 0 and 1). However, survival benefit was not apparent in PS 2 patients. As with the tests for heterogeneity across other subgroups, the trend across the levels of performance status was not statistically significant but the PS 2 patients were the only subgroup in which there appeared to be no treatment effect. This was not because poorer performance status patients received less treatment. They received a comparable number of courses of chemotherapy as other patients. The investigation of subgroups within the meta-analysis data [1] showed no difference in the effect of chemotherapy for good (PS 0 and 1) and poor (PS 2, 3 and 4) performance status, and the subgroup of PS 2 patients in our study was fairly small (n = 159) but our findings are consistent with other studies [8] and therefore need confirmation.
The findings from the subgroup analysis are particularly important given the recent trend to exclude PS 2 patients from major chemotherapy trials. In a Southwest Oncology Group trial [10] , for example, PS 2 patients were excluded from the onset whilst in an Eastern Cooperative Oncology Group trial unexpected excessive toxicity was observed in PS 2 patients and hence the protocol was amended during the trial to exclude these patients [11] .
Symptomatic improvement is valued highly by patients [12] and this is therefore an important element when deciding on the appropriate treatment for PS 2 patients. In contrast to the apparent lack of survival benefit, those patients with poorer performance status at diagnosis (i.e. PS 2) gained the most in symptomatic improvement. Almost by definition, PS 2 patients will have a poorer quality of life at diagnosis and hence more scope for chemotherapeutic palliation, but also greater vulnerability to toxicity. The finding of an overall, shortterm improvement in quality of life in the chemotherapy arm in these cases suggests that symptom palliation outweighed toxicity. The similar dropout rates on the two treatment arms validates the treatment comparison. The greater dropout rate in the PS 2 subgroup may have some effect on the results and could potentially be inflating the observed improvement in this subgroup.
The survival benefit of chemotherapy is now well established in advanced disease and we believe there is no need in general for further randomised trials comparing chemotherapy with palliative care. The growing body of evidence, however, showing the ineffectiveness of chemotherapy in PS 2 patients warrants the need for a randomised clinical trial in such patients to evaluate the survival and quality of life effects of cisplatin-based chemotherapy compared to standard radiotherapy or palliative care. This will ensure that patients with poorer performance status receive optimal treatment in the future.
